A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

J. Mascarenhas; H. Kosiorek; J. Prchal; A. Yacoub; D. Berenzon; M. R. Baer; E. Ritchie; R. T. Silver; C. Kessler; E. Winton; M. C. Finazzi; A. Rambaldi; A. M. Vannucchi; D. Leibowitz; D. Rondelli; M. O. Arcasoy; R. Catchatourian; J. Vadakara; V. Rosti; E. Hexner; M. Kremyanskaya; L. Sandy; J. Tripodi; V. Najfeld; N. Farnoud; M. E. Salama; R. S. Weinberg; R. Rampal; J. D. Goldberg; R. Mesa; A. C. Dueck; R. Hoffman

doi:10.1038/s41375-019-0524-7

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

J. Mascarenhas, H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M. R. Baer, E. Ritchie, R. T. Silver, C. Kessler, E. Winton, M. C. Finazzi, A. Rambaldi, A. M. Vannucchi, D. Leibowitz, D. Rondelli, M. O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. HexnerM. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, M. E. Salama, R. S. Weinberg, R. Rampal, J. D. Goldberg, R. Mesa, A. C. Dueck, R. Hoffman

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	2974-2978
Number of pages	5
Journal	Leukemia
Volume	33
Issue number	12
DOIs	https://doi.org/10.1038/s41375-019-0524-7
State	Published - Dec 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-019-0524-7

Cite this

Mascarenhas, J., Kosiorek, H., Prchal, J., Yacoub, A., Berenzon, D., Baer, M. R., Ritchie, E., Silver, R. T., Kessler, C., Winton, E., Finazzi, M. C., Rambaldi, A., Vannucchi, A. M., Leibowitz, D., Rondelli, D., Arcasoy, M. O., Catchatourian, R., Vadakara, J., Rosti, V., ... Hoffman, R. (2019). A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia, 33(12), 2974-2978. https://doi.org/10.1038/s41375-019-0524-7

Mascarenhas, J, Kosiorek, H, Prchal, J, Yacoub, A, Berenzon, D, Baer, MR, Ritchie, E, Silver, RT, Kessler, C, Winton, E, Finazzi, MC, Rambaldi, A, Vannucchi, AM, Leibowitz, D, Rondelli, D, Arcasoy, MO, Catchatourian, R, Vadakara, J, Rosti, V, Hexner, E, Kremyanskaya, M, Sandy, L, Tripodi, J, Najfeld, V, Farnoud, N, Salama, ME, Weinberg, RS, Rampal, R, Goldberg, JD, Mesa, R, Dueck, AC & Hoffman, R 2019, 'A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis', Leukemia, vol. 33, no. 12, pp. 2974-2978. https://doi.org/10.1038/s41375-019-0524-7

@article{b9a324979a344027ba8aca47083204f0,

title = "A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis",

author = "J. Mascarenhas and H. Kosiorek and J. Prchal and A. Yacoub and D. Berenzon and Baer, {M. R.} and E. Ritchie and Silver, {R. T.} and C. Kessler and E. Winton and Finazzi, {M. C.} and A. Rambaldi and Vannucchi, {A. M.} and D. Leibowitz and D. Rondelli and Arcasoy, {M. O.} and R. Catchatourian and J. Vadakara and V. Rosti and E. Hexner and M. Kremyanskaya and L. Sandy and J. Tripodi and V. Najfeld and N. Farnoud and Salama, {M. E.} and Weinberg, {R. S.} and R. Rampal and Goldberg, {J. D.} and R. Mesa and Dueck, {A. C.} and R. Hoffman",

note = "Funding Information: This study was an investigator-initiated phase 2 clinical trial that was performed in compliance with an Investigational New Drug Application and approved by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai and at all participating sites. It was supported by the National Cancer Institute, and PEG was generously supplied by Roche/Genentech. Funding Information: Conflict of interest J.M. reports clinical trial research support paid to the institution from Incyte, Roche, Novartis, CTI Biopharma, Janssen, Merck, Promedior, and Celgene; clinical trial steering committee and scientific advisory board member: Roche, CTI Biopharma, Incyte, and Celgene. M.R.B. reports clinical trial research support paid to the institution from Abbvie, AI, Astellas, Forma, Incyte, Kite, and Takeda. M.A. reports research grant support paid to institution from Incyte, CTI Biopharma, Samus Therapeutics, Janssen, and Gilead. R.T.S. Funding Information: Acknowledgements This research was made possible by a grant from the National Cancer Institute of the National Institute of Health (MPN Research Consortium Grant, 5P01CA108671–09) and generous independent, unrestricted support from Roche Genentech.",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41375-019-0524-7",

language = "English (US)",

volume = "33",

pages = "2974--2978",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

AU - Mascarenhas, J.

AU - Kosiorek, H.

AU - Prchal, J.

AU - Yacoub, A.

AU - Berenzon, D.

AU - Baer, M. R.

AU - Ritchie, E.

AU - Silver, R. T.

AU - Kessler, C.

AU - Winton, E.

AU - Finazzi, M. C.

AU - Rambaldi, A.

AU - Vannucchi, A. M.

AU - Leibowitz, D.

AU - Rondelli, D.

AU - Arcasoy, M. O.

AU - Catchatourian, R.

AU - Vadakara, J.

AU - Rosti, V.

AU - Hexner, E.

AU - Kremyanskaya, M.

AU - Sandy, L.

AU - Tripodi, J.

AU - Najfeld, V.

AU - Farnoud, N.

AU - Salama, M. E.

AU - Weinberg, R. S.

AU - Rampal, R.

AU - Goldberg, J. D.

AU - Mesa, R.

AU - Dueck, A. C.

AU - Hoffman, R.

N1 - Funding Information: This study was an investigator-initiated phase 2 clinical trial that was performed in compliance with an Investigational New Drug Application and approved by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai and at all participating sites. It was supported by the National Cancer Institute, and PEG was generously supplied by Roche/Genentech. Funding Information: Conflict of interest J.M. reports clinical trial research support paid to the institution from Incyte, Roche, Novartis, CTI Biopharma, Janssen, Merck, Promedior, and Celgene; clinical trial steering committee and scientific advisory board member: Roche, CTI Biopharma, Incyte, and Celgene. M.R.B. reports clinical trial research support paid to the institution from Abbvie, AI, Astellas, Forma, Incyte, Kite, and Takeda. M.A. reports research grant support paid to institution from Incyte, CTI Biopharma, Samus Therapeutics, Janssen, and Gilead. R.T.S. Funding Information: Acknowledgements This research was made possible by a grant from the National Cancer Institute of the National Institute of Health (MPN Research Consortium Grant, 5P01CA108671–09) and generous independent, unrestricted support from Roche Genentech.

PY - 2019/12/1

Y1 - 2019/12/1

UR - http://www.scopus.com/inward/record.url?scp=85069946674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069946674&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0524-7

DO - 10.1038/s41375-019-0524-7

M3 - Letter

C2 - 31363161

AN - SCOPUS:85069946674

SN - 0887-6924

VL - 33

SP - 2974

EP - 2978

JO - Leukemia

JF - Leukemia

IS - 12

ER -

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this